Cellavision Q4’23: Strong growth across the board - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Cellavision Q4’23: Strong growth across the board - Redeye

{newsItem.title}

Redeye’s first take on the Q4 report this morning. Cellavision presented a markedly stronger report straight through the accounts. The top line, finally driven by good development in all regions, was strong, with a healthy 29% organic growth. The gross margin was 68%, which aligned with our expectations. The costs were mostly in line with higher R&D expenses, although there was no enormous difference. Cellavision’s cash flow was positively impacted again by decreased tied-up capital in inventory. The operating cash flow in the quarter amounted to SEK76m (28m). We expect to have a slightly more positive stance on sales progression in 2024e, increasing our base case by roughly 5-10%.

Länk till analysen i sin helhet: https://www.redeye.se/research/975330/cellavision-q423-strong-growth-across-the-board?utm_source=finwire&utm_medium=RSS

Nyheter om CellaVision

Läses av andra just nu

Om aktien CellaVision

Senaste nytt